Carbonyl iron-containing products side-effect data signify "need for caution," FDA says.
This article was originally published in The Tan Sheet
Executive Summary
CARBONYL IRON SIDE-EFFECT STUDIES SIGNIFY "NEED FOR CAUTION", FDA says, in evaluating "the limited evidence concerning the toxicity of carbonyl iron" in dietary supplements, the agency states in its denial of a Feb. 18 Rexall Sundown citizen petition concerning the Jan. 15 final rule on iron-containing drugs and supplements ("The Tan Sheet" Jan. 20, pp. 1-4). Rexall had sought both a reconsideration of the final rule and a stay of the warning label requirement for carbonyl iron-containing products ("The Tan Sheet" March 10, p. 9). Alternatively, Boca Raton, Fla.-based Rexall Sundown had requested a temporary exemption from the warning requirements.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning